Compare Abbott Laboratories (ABT) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Solaredge Technologies Inc — how do they compare? Abbott Laboratories trades at $110.52 (market cap $187.95B), while Solaredge Technologies Inc trades at $32.37 (market cap $2.05B). The key difference: Abbott Laboratories is far larger — about 91.7× Solaredge Technologies Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while Solaredge Technologies Inc pays none. Which is the better fit depends on your goals.
| ABT | SEDG | |
|---|---|---|
Market Cap | $187.95B | $2.05B |
Sector | Health | Technology |
52-Week High | $136.62 | $78.51 |
52-Week Low | $82.57 | $25.10 |
Enterprise Value | $214.96B | $1.91B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
SolarEdge Technologies (SEDG) trades at $32.21, up 1.42% today, amid a volatile period following its Q2 2026 earnings beat but weak Q3 guidance. The technical outlook is bearish with key support at $30, while fundamentals show revenue of $1.18B in 2025 but a net loss of -$405M, reflecting margin pressures. Analyst sentiment is mixed with a $35.15 consensus target, but recent downgrades highlight execution risks.
The stock faces headwinds from U.S. residential market challenges and policy dependence, though European growth offers some upside. Risks include high debt and persistent losses, but cost controls and storage expansion could support a turnaround if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
